Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.

Pharmacogenetics - 1 Aug 1999

Kashuba A D, Nafziger A N, Kearns G L, Leeder J S, Gotschall R, Gaedigk A, Bertino J S

Abstract excerpt

We evaluated the utility of the 3-methoxymorphinan/dextromethorphan (3MM/DM) urinary ratio to reflect baseline CYP3A activity, and its ability to discriminate moderate CYP3A inhibition during fluvoxamine therapy. For 4 months, oral dextromethorphan 30 mg and intravenous midazolam 0.025 mg/kg were administered to nine men every 14 days, and to 10 premenopausal women during the follicular and luteal phases of their...

Topics

Aryl Hydrocarbon Hydroxylases
Cytochrome P-450 CYP2D6
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Enzyme System
Dextromethorphan
Enzyme Inhibitors
Female
Genotype
Humans
Male
Methylation
Oxidoreductases, N-Demethylating
Phenotype

Source

Open in PubMed

Identifiers

PMID: 10780265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics